CARES funds important cancer research
Scientific research funded by CARES and conducted at Cleveland Clinic Taussig Cancer Center is helping to improve the outlook for millions of cancer patients today and in the future. By delving into the biology and genetics of cancer – how it starts, how it grows and spreads and how it reacts to different treatments, scientists in the Lerner Research Institute are advancing the understanding and treatment of this disease. Meet two of the Lerner Research Institute scientists who received CARES research grants in 2005.
Nywana Sizemore, PH.D.
Department of Cancer Biology Lerner Research Institute
Dr. Sizemore’s interest is colorectal cancer. Cancer formation from normal colorectal tissue involves the loss or mutation of certain suppressor genes. One of these is the mutated colorectal cancer (MCC) tumor suppressor gene. These genes inhibit the activation of specific cellular pathways and genes necessary to transform normal colorectal cells into cancer cells. Dr. Sizemore and colleagues are investigating the mechanism by which MCC prevents colorectal cancer formation and progression. One potential application of their research is predicting colorectal cancer patient survival by the presence or absence of this mutated gene.
Graham Casey, Ph.D.
Section Head, Colorectal Cancer Research Department of Cancer Biology Lerner Research Institute
Dr. Casey’s special interest is in the biology of metastatic human breast cancer. A specific gene, the BRMS1 gene has been shown in the laboratory to substantially reduce breast cancer metastasis (spread). If scientists can understand how this gene suppresses metastasis, it would open a new pathway for treating metastatic breast cancer. Dr. Casey and colleagues are investigating the biologic pathways in cells that are regulated by BRMSI and whether they represent targets for therapeutic intervention.